To validate the association of NMD efficiency with immunotherapy response, we analyzed independent datasets that had both RNA-seq and WGS/WES available: (i) Liu et al. [76], comprising 144 melanoma patients treated with anti-PD-1 immune checkpoint inhibitors (ICI); ii) Carroll et al. [80], involving 35 esophageal adenocarcinoma (EAC) patients who underwent first-line immunochemotherapy followed by chemotherapy; (iii) Motzer et al. [81], consisting of 886 patients with advanced renal cell carcinoma (RCC) treated with anti-PD-L1 or anti-PD-1. The gene discussed is CD274; the disease is esophageal adenocarcinoma.